Effect of IDH gene mutation on acute myeloid leukemia
10.3969/j.issn.1674-8115.2018.08.017
- Author:
Qing-Li LI
1
Author Information
1. Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Acute myeloid leukemia (AML);
D-2-hydroxyglutarate (D-2-HG);
Gene mutation;
Isocitrate dehydrogenase (IDH);
Isocitrate dehydrogenase inhibitor;
Tumor metabolites
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(8):960-966
- CountryChina
- Language:Chinese
-
Abstract:
Isocitrate dehydrogenase (IDH) is an important metabolic enzyme involved in the tricarboxylic acid cycle. In recent years, IDH has become the most frequent tumor metabolic mutation gene in acute myeloid leukemia (AML). Unlike other mutations, it gains new functions which can catalyze α-ketoglutarate (α-KG) to produce the tumor metabolite D-2-hydroxyglutarate (D-2-HG). The increased D-2-HG in the cells can affect bone marrow cell differentiation and proliferation and induce myeloid tumors by the genetic controls, cell signaling, bone marrow microenvironment changes and other ways. Currently, the new IDH2 inhibitors AG-221 and IDH1 inhibitors become the first-line drugs targeted therapy in patients with IDH mutations in AML. This paper focused on the mutation of IDH and its mutation characteristics, the formation mechanism of AML by the metabolites produced by mutation, the metabolic pathway of tumor metabolites and the research progress of IDH inhibitors.
